Search the Newsreel

Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Vivid Seats Inc. (NASDAQ:SEAT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.61

VivoSim Labs Regains Nasdaq Compliance After $6M Milestone and $4M Financing

VivoSim Labs announced it has regained compliance with Nasdaq's minimum stockholders’ equity rule following a $5.0 million milestone payment from Eli Lilly, the release of $1.0 million from escrow, and a $4.0 million financing completed in July 2026. The company reported approximately $10.1 million …

VIVO Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for VivoPower PLC (VIVO) stock, based on analyst opinions. It highlights that one analyst has a price target of $10.00, with a max and min estimate of $10.00. The article also includes current stock performance data, …

US$11.61 - That's What Analysts Think Vivid Seats Inc. (NASDAQ:SEAT) Is Worth After These Results

Vivid Seats Inc. (NASDAQ:SEAT) recently released its quarterly results, showing revenue of US$130m, 6.4% above forecasts, while statutory losses were in line with predictions at US$1.30 per share. Following these results, analysts anticipate 2026 revenues to be US$510.6m and foresee a significant reduction in …

VIV|Telefonica Brasil SA|Price:12.010|Chg%:-0.070

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

Vivani Medical announced the completion of enrollment and initial dosing for all 20 participants in its Phase 1 SLIM-1 trial. The trial is evaluating NPM-139, a long-acting semaglutide implant, for chronic weight management, focusing on its safety and tolerability.

Invivyd (IVVD) to Release Earnings on Thursday

Invivyd (IVVD) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts forecasting a loss of $0.15 per share and revenue of $14.4 million. The company's previous quarter missed expectations, and investor sentiment remains mixed, with a …

Vivakor closes $12 million convertible note private placement

Vivakor Inc. (NASDAQ:VIVK) has successfully closed a $12 million convertible note private placement, securing $15 million in principal amount including the original issuance discount. The funds will be used to reduce debt, support working capital, advance its Houston Remediation Processing Center, and further its …

VivoSim Labs regains Nasdaq compliance after cash infusion

VivoSim Labs (NASDAQ:VIVS) has regained compliance with Nasdaq listing rules after receiving a $5.0 million milestone payment from Eli Lilly, a $1.0 million release from escrow, and completing a $4.0 million financing round. These financial infusions, which occurred in July 2026, increased the company's …

Vivani Medical, Inc. (VANI) stock price, news, quote and history

Vivani Medical, Inc. (VANI) is a clinical-stage biopharmaceutical company focused on developing miniaturized subdermal drug implants for chronic diseases. The article provides a comprehensive overview of VANI's stock performance, including its current price, historical data, key financial metrics, and analyst ratings. It also details …

Delta Israel Brands (TASE:DLTI) Stock Rebounds With Profit Surge As Margins Lag

VivoSim regains Nasdaq compliance after $10.1 million cash update

VivoSim Labs (VIVS) has announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders’ equity of $2.5 million. This compliance was achieved through several events in July 2026, including a $5.0 million milestone payment from Eli Lilly, a …

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring a minimum stockholders’ equity of $2.5 million. This compliance was achieved through significant financial events in July 2026, including a $5.0 million milestone payment from Eli Lilly and Company, $1.0 …

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (VIVS) announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a $5.0 million milestone payment and $1.0 million escrow release from Eli Lilly, along with $3.6 million net proceeds from a financing. The company reported $10.1 million cash on hand …

Semaglutide implant trial doses all 20 participants; data expected in November

Vivani Medical announced the successful dosing of all 20 participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management. The trial compares low-dose NPM-139 with Wegovy and focuses on safety, tolerability, pharmacokinetics, and weight change. …

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical announced the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant for chronic weight management. The trial involves 20 GLP-1 naïve participants in Australia and aims to assess the safety, tolerability, and pharmacokinetics …

El Al Israel Airlines (TASE:ELAL) Stock Rebounds As Margin Pressure Persists

Price to earnings forward of VivoPower PLC Class A – TRADEGATE:51J

This page from TradingView provides financial information for VivoPower PLC Class A (TRADEGATE:51J), specifically focusing on its forward price-to-earnings ratio. The page indicates that the market was closed with no trades at the time of viewing. It appears to be a financial data portal, …

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

Vivos Therapeutics announced the issuance of a new US Patent (No. 12,697,190), broadening protection for its Vivos CARE oral medical device technology. This continuation patent, along with a previously issued patent, strengthens the intellectual property around their devices, which have received unprecedented FDA clearances …

Price to earnings forward of Naphtha Israel Petroleum Corp Ltd – TASE:NFTA

VivoPower Ord Shs (VIVO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Innoviva earnings missed by $1.57, revenue topped estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) announced strong second-quarter 2026 financial results, driven by robust performance from its royalty portfolio and significant growth in Innoviva Specialty Therapeutics (IST) net product sales. The company achieved 19% year-on-year total revenue growth to $119.6 million and saw IST U.S. …

Innoviva (NASDAQ:INVA) Announces Quarterly Earnings Results, Misses Expectations By $1.58 EPS

Bezeq (TASE:BEZQ) Stock Faces A Margin Ceiling Despite Profit Progress

VivoSim Labs issues 9,896,718 shares on warrant exercises

VivoSim Labs issued 9,896,718 common shares between July 15 and July 31, 2026, due to the exercise of warrants. This issuance significantly increased the shares outstanding to 13,390,789 as of August 3, 2026, up from 3,194,295 on June 30, 2026. The warrant exercises followed …

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

Invivyd, Inc. (NASDAQ:IVVD) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $8.00. Institutional investors and hedge funds hold a significant 70.36% stake in the company, with some major firms increasing their positions. Despite this, Invivyd's shares opened …

Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology

Vivid Seats (SEAT) Stock Rebounds On World Cup Boosted EBITDA

Vivid Seats (SEAT) stock surged nearly 20% after reporting Q2 2026 earnings, driven by a World Cup boost that delivered $129.9 million in revenue and $12.6 million in adjusted EBITDA. While bulls see this as a sign of operating leverage and efficiency gains, bears …

Tel Aviv Stock Exchange (TASE:TASE) Stock P/E Premium Meets Record Margins

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva (INVA) reported Q2 earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.56, and revenues of $119.59 million, also surpassing estimates by 5.63%. Despite outperforming estimates four times over the past year, the stock currently holds a Zacks Rank #5 (Strong …

Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $119.6M, vs. FactSet Est of $111.0M

Innoviva, Inc. reported its Q2 revenue of $119.6 million, surpassing the FactSet estimate of $111.0 million. The company, a diversified holding company with a focus on healthcare assets and royalties from respiratory products, also announced an update on its equity buyback plan. Innoviva's product …

Vivani Medical (VANI) to Announce Earnings on Wednesday

Vivani Medical (VANI) is set to release its Q2 2026 earnings before market open on Wednesday, August 12th, with analysts expecting a loss of $0.08 per share. The company previously matched consensus estimates with a similar loss in Q1. Insider transactions show Director Gregg …

Vivos sleep apnea devices gain broader protection after new patent

Vivos Therapeutics announced that the U.S. Patent and Trademark Office has issued a new patent, No. 12,697,190, which broadens protection for its Vivos CARE oral medical devices for sleep apnea treatment. This new patent is a continuation of a prior patent from 2024, providing …

Earnings call transcript: TASE posts record Q2 2026 results, shares rise 4.3%